|
시장보고서
상품코드
1574655
세계의 암 항체약물접합체 시장 : 규모, 약제 승인, 약가, 판매, 임상시험 인사이트(2030년)Global Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030 |
||||||
항체약물접합체(ADC)는 모노클로널 항체의 특이성과 세포독성 약물의 효능을 결합한 암 치료의 혁신적 치료제로 등장했습니다. 이 혁신적인 치료법은 안정적인 링커를 통해 세포독성 약물과 결합된 항체로 구성되어 주변 건강한 조직에 대한 손상을 최소화하면서 암세포를 표적화하여 전달할 가능성이 있습니다. 항체약물접합체의 급속한 발전은 임상적, 상업적 성공을 반영하여 현재 다양한 시장에서 16개 제품이 승인되었으며, 2023년 매출은 100억 달러, 2024년 첫 6개월 동안 70억 달러를 돌파할 것으로 예상되고 있습니다. 이러한 성장은 항체약물접합체가 광범위한 암 치료제 시장에서 상업적으로 실행 가능한 분야임을 강조하며, 보다 효과적이고 안전한 후보 화합물을 개발하기 위한 연구개발이 활발히 진행되고 있습니다.
2024년 10월 현재 전 세계 규제 당국은 16종의 항체약물접합체를 승인했으며, 현재 13종이 다양한 암종에 대해 임상적으로 사용할 수 있습니다. 이 중 대표적으로 Padcev, Kadcyla, Enhertu는 2023년 전체 항체 약물 복합제 매출의 약 60%를 차지할 것으로 예상되며, Enhertu는 여러 HER2 양성 고형암 치료제로, Padcev와 Kadcyla는 각각 방광암과 유방암 치료제로만 승인되었습니다. 만 승인되었습니다. 이러한 제품 유형은 치료 가능성뿐만 아니라 다양한 암종에 대한 ADC의 효능에 대한 시장의 신뢰가 높아지고 있음을 보여줍니다.
세계 항암 항체 의약품 복합제 시장은 경쟁적인 상황으로 고형암과 혈액암을 포함한 여러 암을 표적으로 하는 개발이 활발히 진행되고 있습니다. 그러나 그 중에서도 폐암은 현재 가장 광범위한 개발 활동이 이루어지고 있으며, CAB-AXL-ADC, TQB2102, MYTX-011을 포함한 60개 이상의 후보물질이 임상시험 단계에 있으며, 엔허투(Enhertu) 1개가 임상 사용을 승인받았습니다. 이는 여전히 전 세계 암 사망의 주요 원인 중 하나인 폐암에서 미충족 의료 수요가 높은 치료제로의 전략적 전환을 반영합니다. 항체약물접합체는 보다 효과적이고 독성이 낮은 치료 옵션을 제공할 수 있으며, 이 치료 영역에서 특히 매력적입니다.
| 특징 | 상세 |
|---|---|
| 주요 부문 | 용도 : 암 유형별, 지역별, 기술 플랫폼 |
| 대상이 되는 적응증 | 대상 질환 : 폐암, 유방암, 자궁경부암, 췌장암, 식도암, 기타 |
| 주요 대상국 | 미국, 중국, 한국, 캐나다, 인도 등 |
| 대상 약제 | Enhertu, Adcetris, Polivy, Kadcyla 등 |
| 리포트 대상 범위 | 작용기서, ADC 세대, 파이프라인과 승인약 인사이트, 판매 인사이트, 현재의 동향, 향후 기회, 시장 성장 촉진요인·과제 |
| 대상 기업 | Biocytogen, Merck, AstraZeneca, Pfizer, Daiichi Sankyo, ADC Therapeutics 등 |
세계의 암 항체약물접합체 시장에 대해 조사했으며, 시장의 개요와 약제 동향, 임상시험 동향, 지역별 동향 및 시장에 참여하는 기업의 경쟁 구도 등을 제공하고 있습니다.
목차
제1장 항체약물접합체의 서론
- 개요
- 항체약물접합체의 메커니즘
제2장 암표적 치료로서의 항체약물접합체
- 암에서 항체약물접합체의 응용
- 항체약물접합체의 이점
- 항체약물접합체와 기존 치료법의 비교
제3장 항체약물접합체의 세대
- 항체약물접합체 - 진화
- 차세대 항체약물접합체 전망
제4장 시판의 승인 항체약물접합체, 브랜드명, 회사, 적응증별
제5장 세계의 암 항체약물접합체 임상시험 개요
- 상별
- 적응증별
- 기업별
- 환자 부문별
- 국가별
제6장 세계의 암 항체약물접합체 시장 전망
제7장 세계의 암 항체약물접합체 조사와 시장 동향, 지역별
- 미국
- 중국
- 유럽
- 한국
- 호주
- 영국
- 캐나다
- 일본
- 인도
- 라틴아메리카
제8장 세계의 암 항체약물접합체 시장 동향과 발전, 적응증별
- 폐암
- 유방암
- 백혈병
- 난소암
- 소화기 암
- 림프종
- 비뇨생식기 암
- 자궁경부암
- 두경부암
- 뇌종양
- 전립선암
- 췌장암
- 피부암
- 식도암
제9장 암 항체약물접합체 개발 플랫폼, 기업별
제10장 승인된 암 항체약물접합체 - 특허, 투여량, 가격 분석
- Mylotarg
- Adcetris
- Kadcyla
- Besponsa
- Lumoxiti(2023년 시장 철수)
- Polivy
- Padcev
- Enhertu
- Trodelvy
- Blenrep(2023년에 일부 시장 철수)
- Zynlonta
- Tivdak
- Elahere
- Ujvira
- Akalux
- Aidixi
제11장 승인된 암 항체약물접합체 - 판매 인사이트와 2028년 예측
제12장 기업, 국가, 적응증, 상별 세계 암 항체약물접합체 임상시험 인사이트
- 연구
- 전임상
- 제I상
- 제I/II상
- 제II상
- 제II/III상
- 제III상
- 사전 등록
제13장 출시 암 항체약물접합체 기업, 국가, 적응증별 임상적 인사이트
제14장 암 항체약물접합체의 병용요법
제15장 세계의 암 항체약물접합체 시장 개요
제16장 경쟁 구도
- Biocytogen
- Bristol Myers Squibb
- Eli Lilly
- Innovent Biologics
- Merck
- Pfizer
- Affinity Biopharma
- Biokin
- Synaffix
- ADC Therapeutics
- AstraZeneca
- Daiichi Sankyo
- Duality Biologics
- Immunogen
- LigaChem Biosciences
"Global Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030" Report Finding and Inclusions:
- Global Cancer Antibody Drug Conjugates Market: 2020 - 2030
- Global Cancer Antibody Drug Conjugates Market Opportunity > US$ 50 Billion By 2030
- Approved Cancer Antibody Drug Conjugates: 16 Drugs
- Approved Cancer Antibody Drug Conjugates Sales Insights, Patent, Dosage & Price Analysis
- Cancer Antibody Drug Conjugates In Clinical Trials: > 500 Drugs
- Cancer Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication & Phase
- Insight On Commercially Approved Antibody Drug Conjugates By Brand Name, Company & Indication
| Features | Details |
|---|---|
| Key Segments: | Application by Cancer Type, By Region, Technology Platforms |
| Indications Covered: | Lung Cancer, Breast Cancer, Cervical Cancer, Pancreatic Cancer, Pancreatic Cancer, Esophageal Cancer, among others |
| Key Countries Covered: | US, China, South Korea, Canada, India, among others |
| Drugs Covered: | Enhertu, Adcetris, Polivy, Kadcyla, among others |
| Report Coverage: | Mechanism of Action, ADC Generations, Pipeline & Approved Drugs Insight, Sales Insight, Current Trends, Future Opportunities, Market Drivers & Challenges |
| Companies Covered: | Biocytogen, Merck, AstraZeneca, Pfizer, Daiichi Sankyo, ADC Therapeutics, among others |
Antibody drug conjugates (ADCs) have emerged as a transformative class of therapeutics in the cancer treatment landscape, integrating the specificity of monoclonal antibodies with the potency of cytotoxic drugs. These innovative therapies consist of an antibody linked to a cytotoxic agent through a stable linker, allowing targeted delivery to cancer cells while minimizing damage to surrounding healthy tissues. The rapid evolution of antibody drug conjugates reflects their clinical and commercial success, with 16 products currently approved across various markets and sales surpassing US$ 10 Billion in 2023 and US$ 7 Billion in the first 6 months of 2024. This growth highlights antibody drug conjugates as a commercially viable segment of the broader cancer therapeutics market, prompting increased research and development efforts to create more effective and safer candidates.
As of October 2024, regulatory authorities around the world have approved 16 antibody drug conjugates, with 13 currently available for clinical use for different cancer types. Among these, prominent examples include Padcev, Kadcyla, and Enhertu, which collectively accounted for approximately 60% of the total antibody drug conjugates sales in 2023. While Enhertu is indicated for the treatment of several HER2-positive solid cancers, Padcev and Kadcyla are solely approved for the treatment of bladder cancer and breast cancer, respectively. The commercialization of these products demonstrates not only their therapeutic potential but also the market's growing confidence in the effectiveness of ADCs in managing various cancer types.
Global cancer antibody drug conjugates market is characterized by a competitive landscape, with substantial development efforts targeting multiple cancers, including both solid tumors and hematological malignancies. However, out of all these, lung cancer is currently witnessing the most extensive development activity, with over 60 candidates in clinical trials, including CAB-AXL-ADC, TQB2102, and MYTX-011, and one Enhertu, approved for use in clinical setting. This reflects a strategic shift towards addressing the high-unmet medical need in lung cancer, which remains one of the leading causes of cancer mortality worldwide. The potential for antibody drug conjugates to provide more effective and less toxic treatment options makes them particularly attractive in this therapeutic area.
In contrast, however, breast cancer has experienced the highest number of antibody drug conjugates approvals to date, with four approved candidates, contributing significantly to the market's commercial success. Two key players in this domain are the aforementioned Kadcyla and Enhertu, both of which have demonstrated remarkable efficacy and have achieved significant sales milestones. The promising pipeline also includes AstraZeneca and Daiichi Sankyo's Datopotamab Deruxtecan, a TROP2-directed antibody drug conjugate that is currently under review for its use in breast cancer treatment. This continued investment in research and development underscores the critical role antibody drug conjugates play in advancing cancer care.
Regionally, the cancer antibody drug conjugates market is primarily led by the US and China, two of the largest and most dynamic pharmaceutical markets globally. In the US, robust healthcare infrastructure, high R&D expenditure, and a favorable regulatory environment foster innovation and accelerate the approval process for new therapies. Additionally, the presence of major pharmaceutical companies, such as Regeneron, Gilead, Merck and Pfizer, bolsters the competitive landscape, enabling rapid development and commercialization of antibody drug conjugates.
In China, the growing demand for advanced cancer treatments, coupled with increasing government support for biotechnology and pharmaceutical research, has catalyzed significant growth in the antibody drug conjugates sector. Local players like Mabwell, Miracogen, Chia Tai Tianqing Pharmaceutical, Hansoh BioMedical, Sichuan Baili Pharmaceuticals, Biocytogen and Affinity Biopharma are emerging as significant contributors to the market, developing novel Antibody drug conjugates tailored to the specific needs of the Chinese patient population, and out licensing promising candidates to their international counterparts through license agreements.
The global market for cancer antibody drug conjugates represents a dynamic and rapidly evolving segment of the cancer therapeutics landscape. With ongoing clinical trials, innovative research, and increasing regulatory support, antibody drug conjugates are poised to play an increasingly pivotal role in cancer treatment. As efforts continue to address existing challenges and expand the range of approved indications, the future of antibody drug conjugates appears promising, offering hope to patients worldwide in the fight against cancer. The collaborative efforts among pharmaceutical companies, regulatory bodies, and research institutions will be crucial in shaping the next wave of advancements in this exciting therapeutic field.
Table of Contents
1. Introduction To Antibody Drug Conjugates
- 1.1 Overview
- 1.2 Mechanism of Antibody Drug Conjugates
2. Antibody Drug Conjugates As Cancer Targeted Therapy
- 2.1 Applications of Antibody Drug Conjugates in Cancer
- 2.2 Advantages of Antibody Drug Conjugates
- 2.3 Comparison of Antibody Drug Conjugates With Traditional Therapies
3. Generations of Antibody Drug Conjugates
- 3.1 Antibody Drug Conjugates - Evolution
- 3.2 Next Generation Antibody Drug Conjugates Prospects
4. Commercially Approved Antibody Drug Conjugates By Brand Name, Company & Indication
5. Global Cancer Antibody Drug Conjugates Clinical Trials Overview
- 5.1 By Phase
- 5.2 By Indication
- 5.3 By Company
- 5.4 By Patient Segment
- 5.5 By Country
6. Global Cancer Antibody Drug Conjugates Market Outlook
- 6.1 Current Market Scenario
- 6.2 Future Growth Avenues
7. Global Cancer Antibody Drug Conjugates Research & Market Trends by Region
- 7.1 US
- 7.2 China
- 7.3 Europe
- 7.4 South Korea
- 7.5 Australia
- 7.6 UK
- 7.7 Canada
- 7.8 Japan
- 7.9 India
- 7.10 Latin America
8. Global Cancer Antibody Drug Conjugates Market Trends & Development By Indications
- 8.1 Lung Cancer
- 8.2 Breast cancer
- 8.3 Leukemia
- 8.4 Ovarian Cancer
- 8.5 Gastrointestinal Cancer
- 8.6 Lymphoma
- 8.7 Urogenital Cancer
- 8.8 Cervical Cancer
- 8.9 Head & Neck Cancer
- 8.10 Brain Cancer
- 8.11 Prostate cancer
- 8.12 Pancreatic Cancer
- 8.13 Skin cancer
- 8.14 Esophageal cancer
9. Cancer Antibody Drug Conjugates Development Platforms By Company
10. Approved Cancer Antibody Drug Conjugates - Patent, Dosage & Price Analysis
- 10.1 Mylotarg
- 10.1.1 Availability & Patent Insight
- 10.1.2 Pricing & Dosage Insight
- 10.2 Adcetris
- 10.2.1 Availability & Patent Insight
- 10.2.2 Pricing & Dosage Insight
- 10.3 Kadcyla
- 10.3.1 Availability & Patent Insight
- 10.3.2 Pricing & Dosage Insight
- 10.4 Besponsa
- 10.4.1 Availability & Patent Insight
- 10.4.2 Pricing & Dosage Insight
- 10.5 Lumoxiti (Market Withdrawal In 2023)
- 10.5.1 Availability & Patent Insight
- 10.5.2 Pricing & Dosage Insight
- 10.6 Polivy
- 10.6.1 Availability & Patent Insight
- 10.6.2 Pricing & Dosage Insight
- 10.7 Padcev
- 10.7.1 Availability & Patent Insight
- 10.7.2 Pricing & Dosage Insight
- 10.8 Enhertu
- 10.8.1 Availability & Patent Insight
- 10.8.2 Pricing & Dosage Insight
- 10.9 Trodelvy
- 10.9.1 Availability & Patent Insight
- 10.9.2 Pricing & Dosage Insight
- 10.10 Blenrep (Partial Market Withdrawal In 2023)
- 10.10.1 Availability & Patent Insight
- 10.10.2 Pricing & Dosage Insight
- 10.11 Zynlonta
- 10.11.1 Availability & Patent Insight
- 10.11.2 Pricing & Dosage Insight
- 10.12 Tivdak
- 10.12.1 Availability & Patent Insight
- 10.12.2 Pricing & Dosage Insight
- 10.13 Elahere
- 10.13.1 Availability & Patent Insight
- 10.13.2 Pricing & Dosage Insight
- 10.14 Ujvira
- 10.14.1 Availability & Patent Insight
- 10.14.2 Pricing & Dosage Insight
- 10.15 Akalux
- 10.15.1 Availability & Patent Insight
- 10.15.2 Pricing & Dosage Insight
- 10.16 Aidixi
- 10.16.1 Availability Insight
11. Approved Cancer Antibody Drug Conjugates - Sales Insights & Forecast 2028
- 11.1 Adcetris
- 11.2 Padcev
- 11.3 Tivdak
- 11.4 Polivy
- 11.5 Kadcyla
- 11.6 Besponsa
- 11.7 Enhertu
- 11.8 Trodelvy
- 11.9 Zynlonta
- 11.10 Elahere
- 11.11 Blenrep
12. Global Cancer Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication & Phase
- 12.1 Research
- 12.2 Preclinical
- 12.3 Phase I
- 12.4 Phase I/II
- 12.5 Phase II
- 12.6 Phase II/III
- 12.7 Phase III
- 12.8 Preregistration
13. Marketed Cancer Antibody Drug Conjugates Clinical Insight By Company, Country & Indication
14. Cancer Antibody Drug Conjugates Combination Therapies
15. Global Cancer Antibody Drug Conjugates Market Overview
- 15.1 Key Market Growth Drivers
- 15.2 Challenges For Market Growth
16. Competitive Landscape
- 16.1 Biocytogen
- 16.2 Bristol Myers Squibb
- 16.3 Eli Lilly
- 16.4 Innovent Biologics
- 16.5 Merck
- 16.6 Pfizer
- 16.7 Affinity Biopharma
- 16.8 Biokin
- 16.9 Synaffix
- 16.10 ADC Therapeutics
- 16.11 AstraZeneca
- 16.12 Daiichi Sankyo
- 16.13 Duality Biologics
- 16.14 Immunogen
- 16.15 LigaChem Biosciences
